Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)

This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets remains a significant unmet need, despite current lipid-lowering therapies having shown improved CV outcomes in post-ACS patients. Emerging therapies offer promising avenues to further reduce recurrent CV events through different lipid- and lipoprotein-targeted approaches. This report analyzes how current lipid-lowering therapies when added to statin treatment differ based on key attributes and their influence on physicians’ prescribing behavior. It also explores unmet needs in residual CV risk by lipid- and lipoprotein-lowering therapies for secondary prevention in ACS and evaluates whether emerging therapies can address these gaps.

Questions answered

• How do cardiologists evaluate the performance of existing post-ACS lipid-lowering therapies when added to statins across key clinical and non-clinical factors such as efficacy, convenience of administration, and pricing?
• What are the most significant gaps in post-ACS residual CV risk treatment landscape?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• What trade-offs across different clinical attributes (e.g. risk reduction in CV death, mortality or non-fatal myocardial infarction) would cardiologists be willing to make for a new drug for post-ACS?

Geography: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European cardiologists

Key drugs covered: Zetia / Ezetrol, Repatha, Praluent, Nexletol, Vascepa

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Key feature

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.